These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33258102)

  • 1. Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.
    Abo-Aly M; George B; Shokri E; Chelvarajan L; El-Helw M; Smyth SS; Abdel-Latif A; Ziada K
    J Thromb Thrombolysis; 2021 Oct; 52(3):934-940. PubMed ID: 33258102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
    Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
    Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).
    Bulluck H; Chong JH; Bryant J; Annathurai A; Chai P; Chan M; Chawla A; Chin CY; Chung YC; Gao F; Ho HH; Ho AFW; Hoe J; Imran SS; Lee CH; Lim B; Lim ST; Lim SH; Liew BW; Zhan Yun PL; Ong MEH; Paradies V; Pung XM; Tay JCK; Teo L; Ting BP; Wong A; Wong E; Watson T; Chan MY; Keong YK; Tan JWC; Hausenloy DJ;
    Circulation; 2024 Jul; 150(2):91-101. PubMed ID: 38742915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial.
    Ubaid S; Ford TJ; Berry C; Murray HM; Wrigley B; Khan N; Thomas MR; Armesilla AL; Townend JN; Khogali SS; Munir S; Martins J; Hothi SS; McAlindon EJ; Cotton JM
    Thromb Haemost; 2019 Jul; 119(7):1171-1181. PubMed ID: 31129911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Grimfjärd P; Lagerqvist B; Erlinge D; Varenhorst C; James S
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):151-157. PubMed ID: 30698669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
    Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention : A report from the INVEST-STEMI group.
    Silverio A; Bellino M; Scudiero F; Attisano T; Baldi C; Catalano A; Centore M; Cesaro A; Di Maio M; Esposito L; Granata G; Maiellaro F; Muraca I; Musumeci G; Parodi G; Personeni D; Valenti R; Vecchione C; Calabrò P; Galasso G
    J Thromb Thrombolysis; 2024 Jun; 57(5):757-766. PubMed ID: 38615155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
    Alexopoulos D; Pappas C; Sfantou D; Xanthopoulou I; Didagelos M; Kikas P; Ziakas A; Tziakas D; Karvounis H; Iliodromitis E
    J Am Coll Cardiol; 2018 Oct; 72(14):1750-1751. PubMed ID: 30261967
    [No Abstract]   [Full Text] [Related]  

  • 14. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Aytekin A; Ndrepepa G; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Lahu S; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Valina C; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
    Circulation; 2020 Dec; 142(24):2329-2337. PubMed ID: 33115278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and safety of cangrelor in patients with suboptimal P2Y
    Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
    BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
    Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial.
    Gargiulo G; Esposito G; Cirillo P; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Avvedimento M; Tebaldi M; Wahl A; Hunziker L; Billinger M; Heg D; Windecker S; Valgimigli M
    J Cardiovasc Transl Res; 2021 Feb; 14(1):110-119. PubMed ID: 32096064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.